<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666780</url>
  </required_header>
  <id_info>
    <org_study_id>LA-PMCF-01</org_study_id>
    <nct_id>NCT03666780</nct_id>
  </id_info>
  <brief_title>Lifetech LAmbre™ Left Atrial Appendage (LAA) Closure System Post-Market Clinical Follow-up</brief_title>
  <official_title>Lifetech LAmbre™ Left Atrial Appendage Closure System Post-Market Clinical Follow-up MULTI-CENTER, SINGLE-ARM, PROSPECTIVE, POST-MARKET STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lifetech Scientific (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, single-arm, prospective, post-market study of LAmbre™ LAA Closure System. To
      evaluate immediate and long term procedural success of Lifetech LAmbre™ occluders in
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmia causing ischemic stroke. The
      CHA2DS2-VASc score was developed to estimate the stroke rate in patients with non-valvular
      AF, and high scores predict a raised annual stroke risk. The yearly stroke risks without
      treatment in patients with CHA2DS2-VASc score 2 and 9 are 2.2% and 15.2% respectively. For
      patients with increased stroke risk (CHA2DS2-VASc score ≧2), warfarin or other novel oral
      anticoagulants (NOAC) recommended for stroke prevention. Despite the effectiveness of current
      pharmacological therapies for stroke prevention in atrial fibrillation, around 20% of
      patients discontinue therapy - whether new oral anticoagulants (NOAC) or warfarin because of
      side effects and/or bleeding. In addition, warfarin needs to be dosed individually to target
      an international normalized ratio (INR) of 2-3 for striking an optimal balance between
      bleeding and ischemic stroke events. This, combined with drug-drug interaction that occurs
      with both NOACs and warfarin, results in inadequate stroke protection in a substantial
      portion of AF patients. The LAA is the source of 90% of cardiac emboli attributed to stroke
      events. This is a windsock-like structure on the lateral border of the left atrium with
      internal trabeculations, and being a confined space, is prone to blood stasis and thrombus
      formation. Currently, there are surgical, epicardial and percutaneous techniques for
      occluding this structure in order to reduce stroke in AF patients cannot take long term oral
      anticoagulants, and the percutaneous route is intuitively the most attractive given its
      relative non-invasiveness. The two devices in most widespread use for percutaneous LAA
      closure worldwide are the Watchman (Boston Scientific, Natick, MA, USA) and the Amplatzer
      Cardiac Plug (ACP) (Abbott, IL, CA USA). However, both devices have limitations including the
      need for relatively large delivery sheaths (9-14 French) and limited recapture and
      repositioning capabilities.

      LAmbreTM LAA Closure System (Lifetech Scientific, Shenzhen, China) is a novel self-expanding
      LAA occluder constructed from a nitinol mesh and polyester membranes and consists of an
      umbrella and a cover connected by a short central waist. The device is delivered by an 8-10
      French sheath and has full recapture and repositioning capabilities. LAmbreTM LAA Closure
      System received the CE mark in June 2016.

      This PMCF study will be carried out following the CE mark of LAmbreTM LAA Closure System and
      is intended to confirm effectiveness and safety of LAmbreTM LAA Closure System.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of peri-procedural stroke/TIA, device embolization, cardiac or vascular perforation, any other device or procedure related serious adverse event or death (procedure or device related or of unknown cause);</measure>
    <time_frame>7 days</time_frame>
    <description>Peri-procedure defined as within 7 days of the procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Implant success</measure>
    <time_frame>1 day</time_frame>
    <description>Implant success defined as correct positioning and release of the occluder device into the proper anatomical location. Correct positioning is assessed as absence of major residual jet flow (&gt;5mm) into the LAA closure with the device evaluated by transesophageal echocardiogram (TEE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of stroke or systemic embolism or death through 3 years post implantation</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of stroke or systemic embolism or death through 3 years post</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful sealing around the device at the LAA orifice with residual jet ≤5 mm flow measured by TEE at 1-3 months, 6 months post-implantation</measure>
    <time_frame>1-3 months, 6 months post-implantation</time_frame>
    <description>Successful sealing around the device at the LAA orifice with residual jet ≤5 mm flow measured by TEE at 1-3 months, 6 months post-implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device or procedure related Serious Adverse Events (SAEs) from attempted procedure through 3 years post implantation</measure>
    <time_frame>3 years</time_frame>
    <description>Device or procedure related Serious Adverse Events (SAEs) from attempted procedure through 3 years post implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All SAEs (death included) from attempted procedure through 3 years post implantation</measure>
    <time_frame>3 years</time_frame>
    <description>All SAEs (death included) from attempted procedure through 3 years post implantation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Subject</arm_group_label>
    <description>All patients who signed informed consent and are implanted with a LAmbre occluder device will undergo follow-up (FU) evaluations as per local hospital standard and corresponding IFU which is expected to be at the following time points post implant:
At discharge (+/- 1 day)
1-3 months (+/- 1 week)
6 months (+/- 2 weeks)
12 months (+/- 1 month)
2 years (+/- 3 month)
3 years(+/- 3 month) Patients who have undergone a LAmbre explant should remain in the study and adhere to the above mentioned follow-up time point until completion of 3 years follow-up period.
After the patient has completed the 3 years follow-up assessments, the patient is considered to have completed the study. A study exit eCRF needs to be completed and the patient will receive routine care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LAmbre occluder</intervention_name>
    <description>All patients are implanted with a LAmbre occluder device</description>
    <arm_group_label>Subject</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with
        long-term sustainability scheduled for interventional LAA closure.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be at least 18 years of age;

          2. Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with
             long-term sustainability scheduled for interventional LAA closure;

          3. Patient characteristics consistent with the corresponding IFU and sizing guidelines;

          4. The patient or legally authorized representative has been informed of the nature of
             the study, agrees to its provisions and has provided written informed consent,
             approved by the appropriate Ethics Committee (EC);

          5. The patient agrees to comply with requirements of the study including the 3 year
             follow-up.

             .

        Exclusion Criteria:

          1. Any contra-indication mentioned in the corresponding IFU;

          2. Currently participating in other investigational drug- or device studies;

          3. Patient who is pregnant, planning to become pregnant or breast feeding;

          4. Patients cannot tolerate transoesophageal echocardiogram (TEE).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Sievert, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Center Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Xia, Master</last_name>
    <phone>+86 13760184511</phone>
    <email>xiaying@lifetechmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Erik Nielsen Kudsk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Campus Benjamin Franklin (CBF)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Skurk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leif-Hendrik Boldt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Sedaghat</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Brachmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facharztzentrum Dresden-Neustadt GbR</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefen G Spizter, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krupp Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kars Neven</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>habil Boris Schmidt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CardioVasculäres Centrum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horst Sievert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Möbius-Winkler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Sandri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg gGmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Klein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Stephan von Bardeleben</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter Osypka Herzzentrum</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Lewalter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Lam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mater Private Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Walsh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacopo Andrea Oreglia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Tondo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Struttura ASL Roma 2</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achille Gaspardone, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peruga Jan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Freixa Rofastes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Cruz Gonzalez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Odenstedt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mann Chandavimol</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left atrial appendage occluder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

